EP0825995A1

EP0825995A1 - Antibiotics

Info

Publication number: EP0825995A1
Application number: EP96915094A
Authority: EP
Inventors: Edward Borowski; Jolanta Grzybowska; Pawel Sowinski; Jerzy Gumieniak; Andrzej Czerwinski
Original assignee: BTG International Ltd; British Technology Group Ltd
Current assignee: BTG International Ltd
Priority date: 1995-05-13
Filing date: 1996-05-10
Publication date: 1998-03-04
Also published as: IL118233A0; KR19990014843A; AU5698396A; NZ307592A; MX9708637A; AU716883B2; PL308583A1; JPH11504647A; WO1996035701A1; CA2220771A1; PL180253B1; ZA963787B

Abstract

The invention relates to N-alkyl-N-glycosyl derivatives of alkyl esters of antifungal antibiotics of polyene macrolide group of general formula (1a), wherein M represents polyene macrolide antibiotics residues, R represents a variable part of sugar residue, and each of R?1 and R2¿ represents a C¿1-4? alkyl group; their salts of general formula (2a), wherein R, R?1, R2¿ and M are as herein defined and A represents an anion of organic or inorganic acid. Compounds of formula (1b) and (2b) wherein the N-alkyl and alkyl ester groups are represented by methyl are of particular interest. The invention relates also to processes for preparation of the compounds, to compositions containing these compounds and to their use in therapy and the treatment of external and internal fungal infections in humans and animals.

Description

ANTIBIOTICS

The invention relates to N-alkyl-N-glycosyl derivatives of alkyl esters of antifungal antibiotics of the polyene macrolide group of general formula 1(a), wherein M represents polyene macrolide antibiotics residues, R represents a variable part of sugar residue, and each of R* and R which may be the same or different, represents a C_j_4 alkyl group; to salts of compound 1(a), represented by the general formula 2(a), wherein M, R, R^ and R^ are as defined above and A represents an anion of an inorganic or organic acid; to methods of preparation of compounds of general formula 1(a) and 2(a) and their use in medicine.

Compounds of particular interest include N-methyl-N-glycosyl derivatives of methyl esters of antifungal antibiotics of polyene macrolide group of general formula 1(b), wherein M represents polyene macrolide antibiotics residues, wherein R represents a variable part of sugar residue, and their salts of general formula 2(b), wherein M represents polyene macrolide antibiotics residues, wherein R represents a variable part of sugar residue, and A represents an anion of inorganic or organic acid, and to methods of their preparation, and use in medicine. N-alkyl derivatives of antibiotics of polyene macrolide group wherein the amino group of the parent antibiotic is substituted by an alkyl group are known.

N-glycosyl derivatives of polyene macrolides wherein amino group of the parent antibiotic is substituted with a residue of sugar are also known (J. Antibiotics 28, 244 (1975), L. Falkowski, J. Golik, P. Kolodziejczyk, J. Pawlak, J. Zieliήski, T. Zimiήski, E. Borowski; Acta Polon. Pharm. 37, 517 (1980), L. Falkowski, J. Pawlak, J. Golik, P. Kolodziejczyk, B. Stefaήska, E. Bylec, E. Borowski). Examples of sugars used in the preparation of these derivatives include D-glucose, D-mannose, L-rhamnose, D-ribose and maltose. Upon reaction of polyene macrolides with the appropriate sugar a simultaneous Amadori rearrangement occurs to give the corresponding N-glycosyl derivatives. The compounds have the advantage that they exhibit a biological activity similar to those of the starting antibiotics and form water soluble salts. However, the high toxicity associated therewith represents a significant disadvantage.

From papers J. Antibiotics 28, 244 (1975), L. Falkowski, J. Golik, P. Kolodziejczyk, J. Pawlak, J. Zieliάski, T. Zimiήski, E. Borowski; Acta Polon. Pharm. 37, 517 (1980), L. Falkowski, J. Pawlak, J. Golik, P. Kolodziejczyk, B. Stefaήska, E. Bylec, E. Borowski), there are known N-glycosyl derivatives of polyene macrolides, in which the amino group of the parent antibiotic is substituted with a residue of sugar, such as D-glucose, D-mannose, L-rhamnose, D-ribose, maltose. The compounds are prepared by reaction of polyene macrolides with the listed sugars, and simultaneous Amadori rearrangement. The compounds exhibit the biological activity similar to those of the starting antibiotics and form water soluble salts. However, they exhibit high toxicity.

Trimemyl-unmonium derivatives of polyene macrolides methyl esters wherein the amino group of the parent antibiotic is fully methylated to give a quaternary ammonium salt are also known (J. Antibiotics 32, 1080 (1979), L. Falkowski, B. Stefaήska, J. Zieliήski, E. Bylec, J. Golik, P. Kolodziejczyk, E. Borowski). The compounds are prepared by exhaustive methylation of the parent antibiotic with dimethyl sulphate. Advantageous properties of the derivatives include their solubility in water and an antifungal activity similar to that of the starting antibiotics. Unfortunately they are very toxic and unstable.

Another type of derivatives are trimethylammonium derivatives of polyene macrolides methyl esters, which are known from a paper - J. Antibiotics 32, 1080 (1979), L. Falkowski, B. Stefaήska, J. Zieliήski, E. Bylec, J. Golik, P. Kolodziejczyk, E. Borowski and in these compounds the amino group of the antibiotic methyl esters is fully methylated to give quaternary ammonium salt. The compounds are prepared by exhaustive methylation of the parent antibiotic with dimethyl sulphate. The derivatives are soluble in water and are characterized by antifungal activity similar to the activity of the starting antibiotics, but they are very toxic and unstable.

Other types of N-alkyl derivatives include the N-succinimidyl derivatives formed by Michael addition reaction of the antibiotics and N-substituted maleimides, such as: N-ethylmaleimide, N,N'-hexamethylenedimaleimide, N-(3-dimethylaminopropyl)- maleimide; the compounds are known from a paper - J. Antibiotics, 44, 979 (1991), A. Czerwiήski, W.A. Kδnig, T. Zieniawa, P. Sowiήski, V. Sinnwell, S. Milewski, E. Borowski. Such compounds are less toxic than the parent antibiotics, but their antifungal activity is diminished.

Finally, the last known group of N-alkyl derivatives of polyene macrolides are N-enamine and amidine derivatives, formed by reaction of the antibiotics with acetylacetone, ethyl acetylacetate, dimethylacetal or dimethylformamide; the compounds are presented in a paper - Acta Polonica Phann. 45, 71 (1988), B. Stefaήska, J. Zieliήski, E. Borowski, L. Falkowski. The derivatives exhibit antifungal activity similar to those of the parent antibiotics and improved solubility in organic solvents, however, they are still significantly toxic and very unstable. The present inventors have now prepared mixed N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics. Methods of preparation of these mixed compounds have also been established. These novel compounds have been found to have high anti-fungal activity, similar to those of the parent antibiotics; form water soluble salts with acids; and are significantly less toxic. These properties are unexpected since all of the N-alkyl derivatives of polyene macrolides of the prior art exhibit a high toxicity, which is a considerable disadvantage. The compounds comprised by the invention are devoid of this disadvantage.

Until now, N-methyl-N-glycosyl derivatives of methyl esters of polyene macrolide antibiotics and methods of their preparation were unknown. Surprisingly, such compounds preserve high antifungal activity, similar to those of the parent antibiotics, they form water soluble salts with acids, and are dramatically less toxic. These compounds do not exhibit the same toxicity as the N-alkyl derivatives of the prior art. A high toxicity constitutes the basic drawback of all known before N-alkyl derivatives of polyene macrolides, and the compounds comprised by the invention are devoid of this disadvantage. A first aspect of the invention provides N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group of general formula 1(a), wherein M represents residue of an antibiotic of polyene macrolide group, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, and each of R* and R-2, which may be the same or different, represents C_]_4 alkyl group.

M — C00R²

Formula 1(a) Preferably the residue of the antibiotic of polyene macrolide group M is selected from amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin or candicidin.

It is preferred that the mono or oligosaccharide from which the sugar residue R is derived is selected from D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose. Upon reaction of polyene macrolides with the appropriate sugar a simultaneous

Amadori rearrangement occurs to give the N-glycosyl precursors to the compounds of the invention.

A preferred embodiment of the invention comprises N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement.

Formula 1(b)

The invention in its preferred form relates to the derivatives wherein the antibiotic of polyene macrolide group is amphotericin B, or candidin, or candidoin, or candidinin, or mycoheptin, or nystatin, or polyfungin, or aureofacin, or vacidin, or trichomycin or candicidin. A second aspect of the invention provides salts of N-alkyl-N-glycosyl derivatives of antibiotics of polyene macrolide group of general formula 2(a) wherein M, R, R^ and R^ are as defined above for the first aspect of the invention and A represents an anion of an organic or inorganic acid. It is preferred that the salt is a physiologically acceptable salt and compounds wherein A is the anion of L-aspartic acid are especially preferred. Salts wherein R_] and R2 are methyl groups are especially preferred.

Formula 2(a) A preferred embodiment of the second aspect of the invention comprises salts of N- methyl-N-glycosyl derivatives of antibiotics of polyene macrolide group presented by general formula 2(b) wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D- galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, and A represents an anion of organic or inorganic acid.

Formula 2(b) The invention in its preferred form relates to the salts wherein the antibiotic of polyene macrolide group is amphotericin B, or candidin, or candidoin, or candidinin, or mycoheptin. or nystatin, or polyfungin, or aureofacin, or vacidin, or trichomycin or candicidin, and also preferably A relates to the anion of L-aspartic acid.

A third aspect of the invention comprises a method of preparation of compounds of formula 1 (a) wherein M, R, R* and R^ are as defined above for the first and second aspects of the invention and which comprises the steps of reacting a polyene macrolide antibiotic with a mono or oligosaccharide, the reaction being characterised by the occurrence of a simultaneous Amadori rearrangement, to give the N-glycosyl derivatives of the polyene macrolide antibiotics; isolating the product of the Amadori rearrangement; treating the product with an alkylating agent and purifying the crude product.

In one embodiment of the third aspect of the invention the product of the Amadori rearrangement is isolated in the form of a suspension by precipitation from the solution in which the rearrangement occurs. Organic solvents such as N,N-dimethylformamide are preferred to support the Amadori rearrangement. Organic solvents such as diethyl ether are suitable to effect formation of a suspension by precipitation of the product of the Amadori rearrangement.

In a second embodiment of the third aspect of the invention alkylation of the product of the Amadori rearrangement is carried out at reduced temperature. Temperatures of between -5°C and +5°C are preferred. Alkylating agents such as diazo alkanes may be used. An ethereal solution of diazomethane is the preferred alkylating agent.

Crude N-alkyl-N-glycosyl products can be isolated upon removal of the solvent and precipitation from diethyl ether. The pure product may be isolated using known purification procedures.

A preferred embodiment of the third aspect of the invention comprises a process for preparation of the N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D- glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, wherein the obtained by Amadori rearrangement N- glycosyl derivatives of antibiotics of polyene macrolide group are transformed into suspension by precipitation with solvent, preferably diethyl ether, from a solution of the derivatives in organic solvent, preferably in N,N-dimethylformamide, and subsequently treated with ethereal solution of diazomethane at lowered temperature, preferably in the range from -5°C to +5°C, stirred, and isolated by evaporation of solvents, and precipitation from the concentrated solution, preferably by an excess of diethyl ether, then, the crude product is purified according to known procedures. A fourth aspect of the invention provides a method of preparation of salts of N-alkyl-

N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics of general formula 2(a) wherein M, R, R* and R² are as defined above for the first, second and third aspects of the invention and which comprises the steps of suspending an N-alkyl-N-glycosyl derivative prepared according to the third aspect of the invention in sufficient water to effect formation of a homogeneous suspension, acidifying the resulting suspension and isolating the product. The preparation of salts of N-methyl-N-glycosyl derivatives of methyl esters of polyene macrolide antibiotics is especially preferred.

Organic or inorganic acids may be used to acidify the suspension. L-aspartic acid is preferred.

Isolation of the pure product may be effected by precipitation of the crude product with an organic solvent which is then washed with an additional appropriate solvent and dried. It is preferred that the solvent used to precipitate the crude product is miscible with water; acetone is preferred. Typical solvents employed for washing the product include acetone and diethyl ether. It is preferred that the product is dried under reduced pressure.

A preferred embodiment of the fourth aspect of the invention comprises a process for preparation of salts of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 2(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D- glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, wherein the obtained by Amadori rearrangement N- glycosyl derivatives of antibiotics of polyene macrolide group are transformed into suspension by precipitation with solvent, preferably diethyl ether, from a solution of the derivative in organic solvent, preferably in N,N-dimethylformamide, and subsequently treated with ethereal solution of diazomethane at lowered temperature, preferably in the range from -5 °C to +5 °C, stirred, and isolated by evaporation of solvents, and precipitation from the concentrated solution, preferably by an excess of diethyl ether, then the crude product is purified according to known procedures, subsequently, the obtained derivative, as a solid, is suspended in small amount of water, and stoichiometric amount of organic or inorganic acid is added, next the product is precipitated from the formed solution by an excess of organic solvent miscible with water, preferably acetone, the solid is then washed, preferably with acetone and subsequently preferably with diethyl ether, and dried, preferably under reduced pressure.

A fifth aspect of the present invention comprises N-alkyl-N-glycosyl derivatives of formula 1(a) or salts thereof for use in therapy.

A sixth aspect of the invention provides a method for the treatment of fungal infections in humans and animals which comprises the administration thereto of N-alkyl-N- glycosyl derivatives of formula 1(a) or salts thereof as herein before defined. N-methyl-N- glycosyl derivatives of formula 1(b) or the salts thereof are of particular interest.

A first preferred embodiment of the sixth aspect of the invention comprises a method for treatment of external and internal fungal infections in humans and animals, wherein N- methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D- mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement are used to treat the infections.

A second preferred embodiment of the sixth aspect of the invention comprises a method for treatment of external and internal fungal infections in humans and animals, wherein salts of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 2(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, and A represents an anion of organic or inorganic acid are used to treat the infections. A seventh aspect of the invention provides N-alkyl-N-glycosyl derivatives of formula

1(a) or salts thereof as herein before defined for use in the treatment of fungal infections. N-methyl-N-glycosyl derivatives of formula 1(b) or the salts thereof are of particular interest.

The infections for which treatment is provided may be internal or external. The mode of administration will depend upon the nature of the infection. Thus the compounds of the invention may be formulated for intravenous, intra peritoneal, oral, topical, subcutaneous, rectal or vaginal administration.

A eighth aspect of the invention provides compositions for use in the treatment of fungal infections comprising an N-alkyl-N-glycosyl derivatives of formula 1(a) or a salt thereof and a physiologically acceptable carrier. The nature of the N-alkyl-N-glycosyl derivative and the carrier will depend upon the mode of administration. The composition may be formulated from one or more compounds according to the invention, optionally in combination with other known antifungal agents, according to requirements. Compositions containing N-methyl-N-glycosyl derivatives of formula 1(b) or the salts thereof are of particular interest. An ninth aspect of the invention provides a unit dosage form comprising one or more

N-alkyl-N-glycosyl derivative of formula 1(a) or salts thereof and a physiologically acceptable carrier formulated for pharmaceutical or veterinary use. The unit dosage form may be formulated from one or more compounds according to the invention optionally in combination with other known antifungal agents. By analogy with the previous aspects of the invention unit dosage forms containing N-methyl-N-glycosyl derivatives of formula 1(b) are of particular interest.

As mentioned above the nature of the unit dosage form will depend upon the mode of administration. Typically tablets and capsules are suitable for oral administration; creams and patches are suitable for topical administration with pessaries being suitable for rectal and vaginal administration.

A tenth aspect of the invention provides the use of N-alkyl-N-glycosyl derivative of formula 1(a) or salts thereof for the preparation of a medicament for use in the treatment of fungal infections. Compounds wherein the N-alkyl and alkyl ester substituents are both methyl groups are of particular interest. Structural determinations carried out on the compounds of the invention using spectroscopic methods indicate that the integrity of the parent antibiotic is preserved during the reaction.

The invented process for preparation of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group gives the desired products without changes in structure of the parent antibiotic. Structure of the obtained compounds was proved using spectroscopic methods. The proof is illustrated by determination of the structure of N-methyl-N-D-fructosylamphotericin B methyl ester, of formula 3.

Formula 3 Electronic spectrum of N-methyl-N-D-fructosylamphotericin B methyl ester is identical with that of the parent antibiotic, that means amphotericin B, and demonstrates that the invented method does not lead to degradation of the polyene chromophore, and a high value of extinction (E^ι_cm = 1300 at 382 nm) confirms a high purity of the obtained product. Absorption infrared spectrum of the N-methyl-N-D-fructosylamphotericin B methyl ester demonstrates the band related to stretching vibrations of the ester carbonyl group at 1730 cm and lack of band of free carboxylic group, what means that the carboxylic group was completely transformed into methyl ester group. Complete information on structure of the N-methyl-N-D-fructosylamphotericin B methyl ester was provided by nuclear magnetic resonance spectra (NMR) upon 1H (DQF-COSY, ROESY), ^C (DEPT) and heterocorrelated spectra (Varian 300 MHZ spectrometer) allowed an assignment of the formula 3 for the compound. The most significant ^H and *3C information are listed in Tables 1 and 2, respectively. The NMR data for aglycone of amphotericin B are in full agreement with literature data - Magn. Reson. Chem. 30, 275, (1992), P. Sowiήski, J. Pawlak, E. Borowski, P. Gariboldi. ^!H chemical shifts (in DMSO/MeOD solvent system) of N-CH3 (δ = 2.35 ppm) and H-l" (2.30 and 3.15 ppm) are characteristic for influence of an amino substituent. After acidification δ changes to 2.92 ppm for N-CH3, and to 3.64 for H- 1 " due to the protonation of the amino group (δ for H-3' changes to 3.19 ppm). These data are supported also by ROE effects between protons NCH₃/H3', NCH₃/H2' , NCH₃/Hl"b and 1 "a/H3'. Coupling constants and ROE indicate ^ \ conformation of the mycosamine moiety, as it was found before for free amphotericin B.

Table 1 presents chemical shifts *H and ROE effects of the disaccharide fragment of the N-methyl-N-D-fructosylamphotericin B methyl ester.

Table 1 proton δ[ppm] ROE for protons δ[ρpm] ROE for protons pyridine -d_5: methanol-d₄9 : 1 DMSO-d₆ : methanol-d₄ 4 : 6 r 4.77 2', 3', 5', 18b, COOMe 4.48 3', 5'

2' 4.41 1', 3", NMe, 17, COOMe, 1 'a? 4.04 3', NMe, COOMe

J 2.06 1', 2', 5', NMe, 1 "a, COOMe 1.89 l', 2', NMe, l"b

4' 4.38 6' 3.80 6'

5' 3.61 1', 3', 6' 3.45 l'_. 3', 6'

6' 1.23 4', 5' 1.27 4 5' l"a 2.56 3', 3" (2') 2.30 l"b 3.58 NMe 3.15 3", 3'

4.41 l "a? 3.65 l"b

4" 4.76 3.97

5" 4.41 3.63

6"a 4.21 3.57

6^Mb 4.36 3.76

NMe 2.29 2', 3', l"b, COOMe 2.35 2', 3', l"a, l"b, COOMe

COOMe 3.70 1', 2', 3', NMe, 16 3.77 2', NMe Table 2 presents ^ ^C-NMR chemical shifts of the disaccharide fragment of the N-methyl-N- D-fructosylamphotericin B methyl ester and their comparison with data for D-fructose.

Table 2 data for fructoses * β-D-fructopyranose α-D-furanose β-D-fructofuranose carbon δ [ppm] δ [ppm] δ [ppm] δ [ppm] r 98.2

2' 72.4

3' 66.4

4' 69.8

5' 72.3

6' 18.2

1" 62.2 64.1 62.1 63.9

2" 98.1 99.1 105.3 102.4

3" 66.9 70.5 83.0 76.5

4" 71.2 68.4 77.0 75.5

5" 72.2 70.0 82.2 81.5

6" 64.6 64.7 62.1 63.3

NMe 40.9

COOMe 51.6

S. N. Rosenthal & J.H. Fendler, Progr. Phys. Org. Chem. 13, 280 (1976).

Comparison of the data from Table 2 for the fructosyl fragment with literature data for D-fructose indicates the pyranoside form of the sugar substituent. The observed coupling constants, presented in Table 3, evidence a boat conformation of the fructopyranoside ring presented by formula 4. Only this conformation of the ring is in full agreement with the measured coupling constants.

Table 3 presents coupling constants J_jj JJ for protons of the disaccharide fragment of the N-methyl-N-D-fructosylamphotericin B methyl ester (pyήdme-d$: methanol-d4 9 : 1), coupling constants and chemical shifts of closely coupled spin system H3" - H6" were refined iteratively by computer simulation.

Table 3

protons J [Hz] protons J [Hz] l', 2' ~0 l"a, l"b 1 1.6

2', 3' 2.2 3", 4" 1.05

3', 4' 9.5 4", 5" 8.09

4', 5" 9.2 5", 6"a 5.76

5', 6' 6.0 5", 6"b 3.61

6"a, 6"b -10.86

4", 6"a -0.1

The presented results confirm the conformation of the fructosyl fragment of the N-methyl- N-D-fructosylamphotericin B methyl ester presented by formula 4. Other N-methyl-N- glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group were characterized by methods similar to those described above.

Formula 4 The invention will now be described by reference to the following non-limiting examples. Further embodiments falling within the scope of the invention will be apparent to a skilled person. Anti-fungal Activity

For all of the prepared compounds antifungal activity and also toxicity in vitro were determined. For the compound with the best properties, that means for the N-methyl-N-D- fructosylamphotericin B methyl ester aspartate, activity and toxicity in vivo were also determined. In Vitro Antifungal Activity

The antifungal activity of compounds was determined following the standard for polyene macrolides procedure. The liquid Sabouraud medium was inoculated with 10⁴ cells/ml of test organism Candida albicans ATCC 262778 and incubated for 24 hours at 30 °C with the tested antibiotic (serial dilutions). Amphotericin B was used as the reference. Compounds were dissolved in DMF and suitable amounts of the solutions were added to the medium. Turbidimetric method (660 nm) was applied to determine the degree of growth inhibition. The concentration of antibiotic at which the growth of fungi was inhibited by 50% was determined from the dose response curve. The obtained IC50 value characterized antifungal activity of the compound. In Vitro Toxicity

Toxicity of compounds in vitro against animal cells was determined using standard for polyene macrolides procedure, by the determination of the degree of haemolysis of human erythrocytes. Human erythrocytes isolated from fresh, citrated human blood were washed twice with cold saline. The cells were diluted 250 times with saline and equilibrated for 30 minutes at 37 °C. Samples of erythrocytes were incubated with various concentrations of antibiotics (the base solution in DMF) for 30 minutes at 37°C. After centrifugation the lysis of erythrocytes was assessed by determination of the haemoglobin released to the solution. Optical density of the supernatant was measured at 550 nm. The results were expressed by EH50 value, as concentration of antibiotic at which 50% of hemolysis occurred. The values of EH50 were read from a curve relating the degree of hemolysis with antibiotic dose. In Vivo Toxicity In vivo toxicity was determined for methyl ester of N-methyl-N-D- fructosylamphotericin B L-aspartate as the maximum tolerated dose (MTD), and as the acute toxicity (LD50). To determine MTD dose the compound was dissolved in 5% solution of glucose, and administered intravenously and intraperitonealy to Balb/c mice in single and multiple doses. The maximum single tolerated dose was 100 mg/kg for the intravenous and more than 200 mg/kg for the intraperitoneal admiiiistration. The maximum multiple tolerated dose for intraperitoneal administration of 100 mg/kg for 5 days was much higher. For such dose, toxic effects were not observed during 20 days of observation. The acute toxicity, LD50 of methyl ester of N-methyl-N-D-fructosylamphotericin B L-aspartate was determined for Swiss Webster female mice of average weight of 20 g. Various doses of the tested compound, and for comparison, amphotericin B in form of Fungizone, dissolved in 5% glucose were given intravenously to the animals. The administered volume of the solution was 0.5 ml. 0.5 ml of 5 % solution of glucose was administered to mice as a control. Every dose of both preparations was administered to 5 mice. The animals were observed for 7 days. Next, the animals were killed, and some serum indexes were determined. No increased level of aspartate aminotransferase or creatinine were found in comparison with the control. For methyl ester of N-methyl-N-D- fructosylamphotericin B L-aspartate, the LD50 was found to be 400 mg/kg, while for amphotericin B in form of Fungizone it was 6 mg/kg. Chemotherapeutic Efficacy

Chemotherapeutic efficacy of methyl ester of N-methyl-N-D-fructosylamphotericin B L-aspartate was determined using systemic murine candidose model. Candida albicans was grown overnight in Sabouraud dextrose broth at room temperature. The fungal cells were centrifuged, washed twice with 0.9 % solution of sodium chloride, and suspended in physiological salt solution. Female Swiss Webster mice of 25 g weight, were injected intravenously with 10^ cells of Candida in 0.2 ml of 0.9 % sodium chloride solution. Initially, the infection was systemic, but by 2 to 3 days it was localized to the kidneys. Untreated animals usually died between 7 to 14 days post-infection. Three days post-infection, animals were treated intravenously, twice a day, for 5 consecutive days with a 5 to 6 hours interval. Preparation was administered as a solution in 5% glucose. The animals were observed for 5 weeks starting from the day of infection. After this time, the surviving animals were sacrificed , their kidneys were removed, homogenized in sterile water, and the homogenate was plated on Sabouraud dextrose agar, and the grown colonies of Candida were counted. The chemotherapeutic effectiveness was represented as a dose of mg/kg, which in the above test resulted in a survival of 50 % of animals, and on clearance of Candida from kidneys of half of the mice. The dose, called ED50, was calculated using a method given in J. Hyg. 27, 493, (1938). The values of ED50 for methyl ester of N-methyl-N-D-fructosylamphotericin B L-aspartate are 2.3 mg/kg based on the survival, and 6 mg/kg based on the kidneys clearance. Preparative Examples N-Methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group, their salts, and methods of preparation are illustrated by the examples given below.

Example I.

1 g of amphotericin B (E^10/°ι _cm = 1350 at 382 nm, MeOH) was dissolved in 15 ml of

N,N-dimethylformamide, 0.3 g of D-glucose was added, and the mixture was stirred in darkness at 37°C for 40 hours. Next the reaction was cooled and a solid was precipitated with an excess of diethyl ether. The solid was centrifuged, washed twice with diethyl ether and dried under reduced pressure. To remove an excess of glucose the solid was suspended in 20 ml of water, centrifuged, washed twice with small amount of water, twice with acetone, and next twice with diethyl ether. The product was dried under reduced pressure to give 0.98 g of N-D-fructosylamphotericin B (E^{1 %} _{l cm} = 1200 at 382 nm, MeOH). The product was dissolved, with stirring, in 10 ml of N,N-dimethylformamide and 50 ml of diethyl ether was added to the solution, to give a fine suspension. The suspension was cooled in ice to 0 - 2°C, and freshly prepared diethyl ether solution of 2.5 mole of diazomethane per 1 mole of N-D-fructosylamphotericin B, was added with vigorous stirring. The reaction was followed by thin layer chromatography on silica gel in chloroform - methanol - water 10:6:1 v/v solvent system. After completion of the reaction, what took about 2 hours, the excess of diazomethane and diethyl ether was evaporated under reduced pressure at temperature not higher than 40 °C. The crude product was precipitated from the residue with an excess of diethyl ether, centrifuged, washed twice with diethyl ether, next with n-hexane, and dried under reduced pressure to give 0.95 g of the crude product. Pure N-methyl-N-D-fructosylamphotericin B methyl ester was isolated from the crude product by column chromatography on Merck Silicagel 60, 70 -230 mesh in chloroform - methanol - water 20 : 8 : 1 v/v solvent system. Thus, 0.95 g of the crude product was suspended in the mixture of solvents specified above, and if the product dissolved with difficulties, proportions of the same solvents were changed to 10 : 6 : 1. The undissolved part was centrifuged off, and the supernatant charged on chromatography column, next developed in the solvent mixture listed above, but in proportion 20 : 8 : 1 v/v. The eluate was analysed on silica plates using chloroform - methanol - water 10 : 6 : 1 v/v solvent system. The plates were visualized with cerium sulphate reagent. Fractions of Rf = 0.5 - 0.54 containing pure N-methyl-N-D-fructosyl derivative of amphotericin B methyl ester were collected. The combined fractions were evaporated under reduced pressure. The dry residue was dissolved in small amount of N,N-dimethylformamide, and the product was precipitated with an excess of diethyl ether, the solid was centrifuged, washed twice with diethyl ether and dried in a vacuum desiccator. 0.137 g of N-methyl-N- D-fructosylamphotericin B methyl ester, E* °\_cm = 1300 on 382 nm in methanol, was obtained. The proof of structure was given above in the descriptive part. Antifungal activity of the compound against Candida albicans, determined as it was described above, gave IC50 = 0.12 μg/ml, and toxicity for human erythrocytes, determined as described above, gave EH50 value higher than 350 μg/ml. For comparison, EH5O value for the starting amphotericin B was 1.5 μg/ml. An exact value of EH50 for N-methyl-N-D- fructosylamphotericin B methyl ester could not be determined, as above 350 μg/ml the compound was insoluble under conditions of the experiment.

Example II.

0.5 g of candidin (E^{1 %} _{l cm} = 1175 at 382 nm, MeOH) and 0.15 g of D-glucose were dissolved in 10 ml of N,N-dimethylformamide and stirred at 37°C for 36 hours. Further procedure was analogous to this of the Example I, and resulted in 0.43 g of N-D-fructosylcandidin, E^ ^/°\_cm = 1100 at 382 nm in MeOH. The product was methylated with diazomethane in diethyl ether, analogously as in the Example I to give 0.4 g of crude product. Pure N-methyl-N-D-fructosylcandidin methyl ester was isolated by column chromatography, by method similar to that given in the Example I. Fractions containing pure derivative were characterized on thin layer chromatography by Rf = 0.49 - 0.52. The fractions were combined, evaporated to dryness, dissolved in small amount of N,N-dimethylformamide, and solid was precipitated with diethyl ether. The solid was centrifuged, washed with diethyl ether and dried in vacuum desiccator to give 0.05 g of N-methyl-N-D-fructosylcandidin methyl ester; E¹⁰°ι_cm = 1200 at 382 nm, in MeOH, IC50 = 0.75 μg/ml and EH5O above 300 μg/ml. Structure of the compound was determined by the same methods as for of N-methyl-N-D-fructosylamphotericin B methyl ester.

Example III.

2 g of nystatin (E ^'■ \_cm = 870 at 304 nm, in MeOH) and 0.6 g of D-glucose were dissolved in 35 ml of N,N-dimethylacetamide and stirred at 37°C for 40 hours. After completion of the reaction the crude product was precipitated with diethyl ether, centrifuged, and dried under vacuum. Then, an excess of glucose was washed off with small amount of water - acetone 1 : 1 mixture, next with acetone, diethyl ether, and the product was centrifuged and dried in vacuum desiccator to give 1.2 g of N-D-fructosylnystatin (E^_{j cm} = 720 at 304 nm, in MeOH). The product was methylated using diazomethane as in the Example I to give 1.25 g of crude product. The product was purified on silica gel column as in the Example I. Fractions containing pure N-methyl-N-D- fructosylnystatin methyl ester were characterized on thin layer chromatography by Rf = 0.49 - 0.52 as in the Example I. The fractions were combined, evaporated to dryness at 30°C under reduced pressure, dissolved in small amount of N,N-dimethylformamide, and product was precipitated with diethyl ether. The product was centrifuged, washed with diethyl ether and dried in vacuum desiccator to give 0.17 g of N-methyl-N-D- fructosylnystatin methyl ester; E \_cm = 900 at 304 nm, in MeOH. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester. For the obtained compound IC5 = 6.8 μg/ml and EH5O above 300 μg/ml were found.

Example IV.

0.79 g of vacidin. the main component of antibiotic complex aureofacin, (E* \_cm = 900 at 378 nm. in MeOH) and 0.22 g of D-glucose in 15 ml of N.N-dimethylacetamide were stirred at 37°C for 18 hours. After completion of the reaction the mixture was cooled and solid was precipitated with an excess of diethyl ether. The solid was centrifuged, washed with diethyl ether and dried under reduced pressure to give 0.8 g of crude N-D- fructosylvacidin (E^10/°ι_cm = 720 at 378 nm, in MeOH). The obtained derivative was methylated using diazomethane, as in the Example I to give 0.5 g of crude product. Pure N-methyl-N-D-fructosylvacidin methyl ester was isolated by chromatography on silica gel column similarly as it was described in the Example I, but the column was developed with chloroform - methanol - water 30 : 8 : 1 solvent system. Fractions containing pure derivative of vacidin and having on thin layer chromatography value of Rf = 0.53 - 0.55 in chloroform - methanol - water 13 : 8 : 1 solvent system were collected and combined. Further procedure was as in the Example III. 0.07 g of N-methyl-N-D-fructosylvacidin methyl ester was obtained (E* \_cm = 900 at 378 nm, in MeOH). The compound exhibited IC50 = 0.01 μg/ml and EH5O = 170 μg/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester.

Example V.

0.79 g of candicidin D, the main component of antibiotic complex candicidin, was treated identically as described in the Example IV. 0.1 g of N-methyl-N-D-fructosylcandicidin D methyl ester was obtained; E* \ _m = 920 at 378 nm, in MeOH, Rf of the compound in thin layer chromatography, under conditions described in the Example IV, was 0.50 - 0.53. The compound exhibited IC50 = 0.01 μg/ml and EH5O = 180 μg/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester.

Example VI.

0.79 g of the main component of antibiotic complex trychomycin was treated identically as it was described in the Example IV. 0.1 g of N-methyl-N-fructosyltrychomycin methyl ester was obtained; E^^0/°ι_cm = 910 at 378 nm, in MeOH Rf of the compound in thin layer chromatography, under conditions described in the Example IV, was 0.49 - 0.52. The compound exhibited IC50 = 0.013 μg/ml and EH5O = 165 μg/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester.

Example VII.

0.5 g of amphotericin B (E^ '⁰\_cτΑ = 1350 at 382 nm, MeOH) and 0.15 g of L-glucose in 8 ml of N,N-dimethylformamide was stirred at 37°C for 40 hours. Subsequent operations were as in the Example I. 0.065 g of N-methyl-N-L-fructosylamphotericin B methyl ester was obtained; E* \_cm = 1280 at 382 nm, in MeOH. The compound exhibited IC50 = 0.42 μg/ml and EH5O = above 200 μg/ml. Structure of the compound was determined by a method described for methyl ester of N-methyl-N-D- fructosylamphotericin B.

Example VIII.

0.52 g of amphotericin B (E^{1 %} _{l cm} = 1350 at 382 nm, MeOH) and 0.153 g of D-mannose was dissolved in 10 ml of N,N-dimethylformamide and stirred at 37 °C for 40 hours. Subsequent operations were as in the Example I. Pure derivative was isolated by silica gel column chromatography, in a manner analogous to that of the Example I, fractions having in thin layer chromatography, run according to the method described in the Example I, value of Rf = 0.53 - 0.55 were collected. Subsequent operations were as in the Example I. 0.08 g of N-methyl-N-D-fructosylamphotericin B methyl ester was obtained; E^{1 %} _{l cm} = 1280 at 382 nm, in MeOH. The compound exhibited IC5O = 0.42 μg/ml and EH50 above 200 μg/ml. Structure of the compound was determined by a method described for N-methyl-N-D-fructosylamphotericin B methyl ester.

Example IX.

0.5 g of amphotericin B (E^{1 %} _{l cm} = 1350 at 382 nm, MeOH) and 0.3 g of D-lactose in 12 ml of N,N-dimethylformamide was stirred at 37°C for two days. Subsequent operations were as in the Example I. Pure derivative was isolated by silica gel column chromatography, in a manner analogous to that of the Example I, fractions having in thin layer chromatography. run according to the method described in the Example I. value of Rf = 0.25 - 0.30 were collected. 0.08 g of N-methyl-N-D-fructosyl-galactosylamphotericin B methyl ester was obtained; E*- ⁰\_cm = 1000 at 382 nm, in MeOH. The compound exhibited IC50 = 6.0 μg/ml and EH5O above 200 μg/ml.

Example X.

0.5 g of N-methyl-N-D-fructosylamphotericin B methyl ester, prepared according to the Example I, was suspended in 10 ml of water and 0.059 g of aspartic acid dissolved in 2 ml of water was added. The solution of acid was added dropwise, with stirring to effect the solution. The solution was filtered to remove a small amount of residual solid and an excess of acetone was added to the clear filtrate until the whole salt was precipitated. The solid was filtered off or centrifuged, washed twice with acetone, twice with diethyl ether and dried under reduced pressure, 0.5 g of methyl ester of N-methyl-N-D- fructosylamphotericin B L-aspartate, E^ '⁰\_cm = 1100 at 382 nm, in MeOH, was obtained. Thin layer chromatography under conditions as in the Example I gave Rf = 0.5 - 0.54. Product was soluble in N,N-dimethylformamide, dimethylsulphoxide and 5% water solution of glucose. It was very well soluble in water. The compound exhibited IC50 = 0.125 μg/ml and EH50 above 350 μg/ml.

Claims

1. N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group of general formula 1 (a), wherein M represents residue of an antibiotic of polyene macrolide group, R represents a part of sugar residue formed by reaction of the antibiotic with a mono or oligosaccharide, and each of R* and R which may be the same or different, represents a C_j .4 alkyl group.

M — C00R²

Formula 1(a)

2. N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group according to claim 1 wherein M is selected from amphotericin B, candidin, candidoin, candidinin, mycoheptin, nystatin, polyfungin, aureofacin, vacidin, trichomycin or candicidin.

3. N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group according to either claim 1 or 2 wherein the mono or oligosaccharide from which the sugar residue R is derived is selected from D-glucose, or L-glucose, or D- mannose, or D-galactose, or lactose, or maltose.

4. N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group according to any one of claims 1 to 3 wherein R* and R² are methyl groups.

5. Salts of N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group of' general formula 2(a) wherein M, R, R* and R² are defined according to any one of claims 1 to 4 and A represents an anion of an organic or inorganic acid.

-27-

Formula 2(a)

6. Salts of N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group according to claim 5 wherein A is the anion of L-aspartic acid.

7. A method of preparation of N-alkyl-N-glycosyl derivatives of alkyl esters of antibiotics of polyene macrolide group as defined in any one of claims 1 to 4 which comprises the steps of reacting a polyene macrolide antibiotic with a mono or oligosaccharide, the reaction being characterised by the occurrence of a simultaneous Amadori rearrangement, to give the N-glycosyl derivatives of the polyene macrolide antibiotics; isolating the product of the Amadori rearrangement; treating the product with an alkylating agent and purifying the crude product.

8. A method of preparation according to claim 7 wherein product of the Amadori rearrangement is isolated in the form of a suspension by precipitation from the solution in which the rearrangement occurs.

9. A method of preparation according to claim 7 or claim 8 wherein N,N- dimethylformamide is used to support the Amadori rearrangement.

10. A method of preparation according to any one of claims 7 to 9 wherein diethyl ether is used to effect formation of a suspension by precipitation of the product of the Amadori rearrangement.

1 1. A method of preparation according to any one of claims 7 to 10 wherein alkylation of the product of the Amadori rearrangement is carried out at reduced temperature.

12. A method of preparation according to claim 10 wherein alkylation is carried out at temperatures of between -5°C and +5°C.

A method of preparation according to any one of claims 7 to 12 wherein the alkylating agent is an ethereal solution of diazomethane.

14. A method of preparation of salts of N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics of general formula 2(a) as defined in claim 5 or claim 6 which comprises the steps of suspending an N-alkyl-N-glycosyl derivative prepared according to any one of claims 7 to 13 in sufficient water to effect formation of a homogeneous suspension, acidifying the resulting suspension and isolating the product.

15. A method of preparation of salts of N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to claim 14 wherein organic or inorganic acids are used to acidify the suspension.

16. A method of preparation of salts N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to claim 15 wherein L-aspartic acid is used to acidify the suspension.

17. A method of preparation of salts N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to any one of claims 14 to 16 wherein isolation of the pure product is effected by precipitation of the crude product with an organic solvent followed by subsequent washing with an additional appropriate solvent and drying.

18. A method of preparation of salts N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to any one of claims 14 to 17 wherein the solvent used to precipitate the crude product is miscible with water.

19. A method of preparation of salts N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to claim 18 wherein the solvent is acetone.

20. A method of preparation of salts N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to any one of claims 17 to 19 wherein the additional appropriate solvents employed for washing the product are selected from acetone and diethyl ether.

21. A method of preparation of salts N-alkyl-N-glycosyl derivatives of alkyl esters of polyene macrolide antibiotics according to any one of claims 14 to 20 wherein the product is dried under reduced pressure.

22. N-alkyl-N-glycosyl derivatives of formula 1(a) or salts thereof according to any one of claims 1 to 6 for use in therapy.

23. A method for the treatment of fungal infections in humans and animals which comprises the administration thereto of N-alkyl-N-glycosyl derivatives of formula 1(a) or salts thereof according to any one of claims 1 to 6.

24. A method for the treatment of fungal infections in humans and animals which comprises the administration thereto of N-methyl-N-glycosyl derivatives of formula

1(a) or salts thereof according to any one of claims 1 to 6.

25. A composition for use in the treatment of fungal infections comprising an N-alkyl-N- glycosyl derivative of formula 1 (a) or salts thereof according to any one of claims 1 to 6 and a physiologically acceptable carrier.

26. A unit dosage form comprising one or more N-alkyl-N-glycosyl derivative of formula 1(a) or salts thereof and a physiologically acceptable carrier formulated for pharmaceutical or veterinary use.

27. A composition for use in the treatment of fungal infections according to claim 25 or a unit dosage form according to claim 26 wherein the N-alkyl-N-glycosyl derivative of formula 1(a) or salts thereof includes N-methyl-N-glycosyl derivatives of the methyl esters of formula 1(b) or the salts thereof.

28. A composition or unit dosage form according to any one of claims 25 to 27 which further comprises a known anti-fungal agent.

29. A composition or unit dosage form according to any one of claims 25 to 28 which is formulated for intravenous, intra peritoneal, oral, topical, subcutaneous, rectal or vaginal administration.

30. Use of N-alkyl-N-glycosyl derivatives of alkyl esters of formula 1(a) or salts thereof according to any one of claims 1 to 6 for the preparation of a medicament for use in the treatment of fungal infections.

31. Use according to claim 30 wherein the N-alkyl and alkyl ester substituents are both methyl groups.

32. Use of N-alkyl-N-glycosyl derivative of formula 1(a) or salts thereof according to any one of claims 1 to 6 for the treatment of fungal infections.

33. Use according to claim 32 wherein the N-alkyl and alkyl ester substituents are both methyl groups.

34. Use according to claim 32 or claim 33 wherein the fungal infection is external or internal.

35. N-Methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D- glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement.

Formula 1(b)

36. Derivatives according to claim 37, wherein the antibiotic of polyene macrolide group is amphotericin B, or candidin, or candidoin, or candidinin, or mycoheptin, or nystatin, or polyfungin, or aureofacin, or vacidin, or trichomycin or candicidin.

37. Salts of N-methyl-N-glycosyl derivatives of antibiotics of polyene macrolide group presented by general formula 2(b) wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, and A represents an anion of organic or inorganic acid.

Formula 2(b)

38. Salts, according to claim 39, wherein the antibiotic of polyene macrolide group is amphotericin B, or candidin, or candidoin, or candidinin, or mycoheptin, or nystatin, or polyfungin, or aureofacin, or vacidin, or trichomycin or candicidin.

39. Salts according to claims 39 or 40, wherein A relates to the anion of L-aspartic acid.

40. Process for preparation of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D- galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, wherein the obtained by Amadori rearrangement N-glycosyl derivatives of antibiotics of polyene macrolide group are transformed into suspension by precipitation with solvent, preferably diethyl ether, from a solution of the derivative in organic solvent, preferably in N,N-dimethylformamide, and subsequently treated with ethereal solution of diazomethane at lowered temperature, preferably in the range from -5 °C to +5°C, stirred, and isolated by evaporation of solvents, and precipitation from the concentrated solution, preferably by excess of diethyl ether, the crude product is purified according to known procedures.

41. Process for preparation of salts of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(b), wherein

M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D- galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, wherein the obtained by Amadori rearrangement N-glycosyl derivatives of antibiotics of polyene macrolide group are transformed into suspension by precipitation with solvent, preferably diethyl ether, from a solution of the derivative in organic solvent, preferably N.N-dimethylformamide, and subsequently treated with ethereal solution of diazomethane at lowered temperature, preferably in the range from -5°C to +5°C, stirred, and isolated by evaporation of solvents, and precipitation from the concentrated solution, preferably by an excess of diethyl ether, the crude product is purified according to known procedures, subsequently, the obtained derivative, as a solid, is suspended in small amount of water, and stoichiometric amount of organic or inorganic acid is added, next the product is precipitated from the formed solution by an excess of organic solvent miscible with water, preferably acetone, the solid is washed, preferably with acetone and subsequently preferably with diethyl ether, and dried, preferably under reduced pressure.

42. Method for treatment of external and internal fungal infections in humans and animals, wherein N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 1(a) 1, wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D-galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement are used to treat the infections.

43. Method for treatment of external and internal fungal infections in humans and animals, wherein salts of N-methyl-N-glycosyl derivatives of methyl esters of antibiotics of polyene macrolide group presented by general formula 2(b), wherein M represents residue of an antibiotic of polyene macrolide group, wherein R represents a part of sugar residue formed by reaction of the antibiotic with mono or oligosaccharide, preferably with D-glucose, or L-glucose, or D-mannose, or D- galactose, or lactose, or maltose, and by simultaneous Amadori rearrangement, and A represents an anion of organic or inorganic acid are used to treat the infections.